R. Lehman

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

E. Winer, C. Hudis, L. Norton, 2011, Clinical Cancer Research.

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

S. Chandarlapaty, C. Hudis, C. Swanton, 2013, Breast Cancer Research.

A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.

S. Chandarlapaty, C. Swanton, Y. Janjigian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer

E. Winer, C. Hudis, L. Norton, 2013, Cancer.

Abstract P1-13-11: Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a phase 2, single-arm feasibility study

D. Lake, C. Hudis, A. Seidman, 2012 .

A phase II, single-arm, feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate for the adjuvant treatment of early-stage breast cancer (EBC).

C. Hudis, T. Traina, A. Seidman, 2012 .

Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

E. Winer, C. Hudis, L. Norton, 2013, Journal of Clinical Oncology.